Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABBV

Abbvie Inc

Mar 02 • 04:00PM ET

234.26

+2.18 0.94 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO IVV SPY VTV XLV SCHD VIG IWF VYM

Scroll to Statements

Index	S&P 500	P/E	99.20	EPS (ttm)	2.36	Insider Own	0.13%	Shs Outstand	1.77B	Perf Week	2.08%
Market Cap	414.21B	Forward P/E	14.48	EPS next Y	16.18	Insider Trans	-0.96%	Shs Float	1.77B	Perf Month	6.27%
Enterprise Value	477.18B	PEG	0.68	EPS next Q	3.02	Inst Own	75.76%	Short Float	1.30%	Perf Quarter	2.90%
Income	4.19B	P/S	6.77	EPS this Y	45.65%	Inst Trans	1.28%	Short Ratio	3.56	Perf Half Y	12.67%
Sales	61.16B	P/B	-	EPS next Y	11.09%	ROA	3.11%	Short Interest	22.88M	Perf YTD	2.53%
Book/sh	-1.85	P/C	78.79	EPS next 5Y	21.31%	ROE	15221.82%	52W High	244.81 -4.31%	Perf Year	12.07%
Cash/sh	2.97	P/FCF	23.25	EPS past 3/5Y	-29.11% -2.81%	ROIC	7.43%	52W Low	164.39 42.50%	Perf 3Y	51.74%
Dividend Est.	6.82 (2.91%)	EV/EBITDA	16.88	Sales past 3/5Y	1.75% 5.95%	Gross Margin	70.12%	Volatility	2.37% 2.76%	Perf 5Y	117.21%
Dividend TTM	6.65 (2.84%)	EV/Sales	7.80	EPS Y/Y TTM	-1.34%	Oper. Margin	32.81%	ATR (14)	5.96	Perf 10Y	320.57%
Dividend Ex-Date	Apr 15, 2026	Quick Ratio	0.56	Sales Y/Y TTM	8.57%	Profit Margin	6.84%	RSI (14)	60.59	Recom	1.85
Dividend Gr. 3/5Y	5.21% 6.56%	Current Ratio	0.67	EPS Q/Q	5724.31%	SMA20	3.58%	Beta	0.33	Target Price	255.08
Payout	281.66%	Debt/Eq	-	Sales Q/Q	10.04%	SMA50	4.38%	Rel Volume	1.16	Prev Close	232.08
Employees	57000	LT Debt/Eq	-	Earnings	Feb 04 BMO	SMA200	10.23%	Avg Volume	6.43M	Price	234.26
IPO	Dec 10, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.15% 1.25%	Trades		Volume	7,427,146	Change	0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$260
Feb-20-26	Initiated	Barclays	Overweight	$275
Jan-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-07-26	Resumed	UBS	Neutral	$240
Dec-10-25	Upgrade	HSBC Securities	Hold → Buy	$265
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$280
Nov-04-25	Downgrade	DZ Bank	Buy → Hold	$237
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203

Show Previous Ratings

Mar-02-26 06:50PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
12:28PM	AbbVie Says 55% Of Crohn's Patients Reached Remission With Skyrizi, Bolsters Competitive Positioning Against Johnson & Johnson (Benzinga)
08:30AM	AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease (PR Newswire)
02:57AM	Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now? (Insider Monkey)
Feb-27-26 09:40AM	Why AbbVie (ABBV) is a Top Value Stock for the Long-Term (Zacks)
10:40AM	Loading…
Feb-26-26 10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
Feb-25-26 09:24PM	RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears (Insider Monkey)
03:29PM	Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference (MarketBeat)
09:57AM	Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie (Investing.com)
08:01AM	Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested (Benzinga)
07:57AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More (24/7 Wall St.)
Feb-24-26 04:57PM	AbbVie makes $380 million 'made in the U.S.' move (TheStreet)
10:29AM	Is AbbVie Stock Underperforming the Dow? (Barchart)
09:45AM	Here's Why AbbVie (ABBV) is a Strong Growth Stock (Zacks)
09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:00AM	Loading…
08:00AM	AbbVie to Present at the TD Cowen 46th Annual Health Care Conference (PR Newswire)
06:01AM	AbbVie to spend $380M on two 2 manufacturing facilities in Illinois (Manufacturing Dive)
05:37AM	AbbVie announces $380m investment in North Chicago API facilities (Pharmaceutical Business Review)
02:11AM	FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL (Insider Monkey)
Feb-23-26 02:25PM	AbbVie plans to spend $380 million building two new manufacuturing facilities in North Chicago (Chicago Tribune)
01:13PM	Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential (Insider Monkey)
11:00AM	AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States (PR Newswire)
11:00AM	AbbVie plans to spend $380 million building two new manufacturing facilities in North Chicago (Chicago Tribune)
10:35AM	Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings? (Zacks)
08:13AM	Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs (Zacks)
08:02AM	Crown Castle and AT&T Tumble While Coca-Cola Rises as Dividened Stocks Take a Breather (24/7 Wall St.)
Feb-20-26 10:57AM	Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now? (Zacks)
08:16AM	Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026? (Zacks)
08:08AM	Barclays launches U.S. biopharma coverage with four preferred picks (Investing.com)
08:02AM	FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer (Benzinga)
02:00AM	Loading…
02:00AM	U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) (PR Newswire)
Feb-19-26 09:37AM	AbbVie Declares Quarterly Dividend (PR Newswire)
Feb-18-26 09:33PM	Evercore Notes AbbVie Inc.'s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited (Insider Monkey)
03:08AM	The Zacks Analyst Blog AbbVie, RTX, International Business Machines, EVI Industries, and Rocky Mountain Chocolate Factory (Zacks)
Feb-17-26 11:32PM	1 Mega-Cap Stock on Our Watchlist and 2 We Avoid (StockStory)
04:13PM	Top Analyst Reports for AbbVie, RTX & IBM (Zacks)
Feb-16-26 09:50AM	Why AbbVie (ABBV) is a Top Momentum Stock for the Long-Term (Zacks)
07:05AM	AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus (MarketBeat)
Feb-13-26 06:01PM	Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio (GuruFocus.com)
09:57AM	Where is AbbVie Inc. (ABBV) Headed According to the Street? (Insider Monkey)
08:00AM	Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent (Investing.com)
Feb-12-26 12:37PM	This Is Gracos Dividend Score After Paying Investors (24/7 Wall St.)
10:35AM	IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock? (Zacks)
04:42AM	AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform (Insider Monkey)
Feb-11-26 07:49PM	Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable (Insider Monkey)
06:49PM	AbbVie sues US health agency over Botox price controls (Reuters)
06:39PM	Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa (MarketBeat)
12:35AM	The 5 Most Interesting Analyst Questions From AbbVie's Q4 Earnings Call (StockStory)
Feb-10-26 10:29AM	AbbVies $100bn deal aligns drug pricing with domestic manufacturing goals (Pharmaceutical Technology)
09:40AM	Here's Why AbbVie (ABBV) is a Strong Value Stock (Zacks)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:32AM	Here's What Will Drive AbbVie's Top-line Growth in 2026 (Zacks)
08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
Feb-09-26 09:24AM	J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent Loss (Zacks)
09:11AM	Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4? (Zacks)
Feb-08-26 11:41PM	3 Market-Beating Stocks to Research Further (StockStory)
Feb-06-26 01:52PM	CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder (Benzinga)
09:26AM	Have originator medicines list prices started to drop in the US? (Pharmaceutical Technology)
02:15AM	AllianceBernstein Q4 Earnings Call Highlights (MarketBeat)
Feb-05-26 01:29PM	Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. (Barrons.com)
12:32PM	AbbVie's Prognosis: The February Dip Looks Like a Buy Signal (MarketBeat)
11:32AM	Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers waiting game (BioPharma Dive)
10:25AM	Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. (Barrons.com)
09:00AM	Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results (TipRanks)
08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
01:54AM	Analyst Report: AbbVie Inc. (Morningstar Research)
12:32AM	ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds (StockStory)
Feb-04-26 10:08PM	AbbVie Q4 Earnings Call Highlights (MarketBeat)
05:28PM	Stocks to Watch Wednesday Recap: AMD, Super Micro, Chipotle (The Wall Street Journal)
04:57PM	Stock Market Today: Nasdaq Sinks As Tech Sell-Off Intensifies; Alphabet Beats Wall Street Forecasts (Live Coverage) (Investor's Business Daily)
04:41PM	These Stocks Are Todays Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More (Barrons.com)
04:09PM	AbbVie Pummeled After Delivering A Fourth-Quarter Beat - On The Back Of Humira (Investor's Business Daily)
04:01PM	AbbVie Inc (ABBV) Q4 2025 Earnings Call Highlights: Record Revenues and Strategic Growth Plans (GuruFocus.com)
01:44PM	Stock Market Today: Dow Falters, Nasdaq Sinks As Tech Sell-Off Intensifies; This Pharma Stock Falls (Live Coverage) (Investor's Business Daily)
12:38PM	AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth (Benzinga)
12:28PM	AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View (Zacks)
11:06AM	Eli Lilly, Novo Nordisk, AbbVie: Pharma earnings roundup (Yahoo Finance Video)
10:52AM	AbbVie (ABBV) Q4 2025 Earnings Call Transcript (Motley Fool)
10:49AM	ADP Payrolls Come in Way Below Expectations (Zacks)
10:30AM	AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
10:19AM	ADP Jobs Lower, Q4 Earnings Reports Up (Zacks)
09:39AM	Stocks to Watch Wednesday: AMD, Super Micro, Chipotle (The Wall Street Journal)
09:00AM	AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates (Zacks)
08:34AM	AbbVie Revenue Rises on Immunology Growth (The Wall Street Journal)
08:31AM	AbbVie beats Q4 expectations, shares dip (Investing.com)
08:23AM	AbbVie Slumps Despite Widespread Beat, Upbeat Earnings Guidance (Investor's Business Daily)
08:18AM	AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. (Barrons.com)
08:05AM	AbbVie: Q4 Earnings Snapshot (Associated Press Finance)
08:02AM	AbbVie's (NYSE:ABBV) Q4 CY2025: Beats On Revenue (StockStory)
07:50AM	AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs (Reuters)
07:48AM	AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results (PR Newswire)
05:24AM	Uber and Alphabet headline earnings slate (MarketWatch)
04:36AM	Big Tech and Pharma Earnings: What to Watch This Week (The Wall Street Journal)
04:24AM	Stock Market Today: Dow, S&P 500 and Nasdaq consolidate after software rout; AMD results weigh; Alphabet earnings on tap; gold recovers $5,000 level. (MarketWatch)
Feb-03-26 07:00PM	Alphabet earnings, Eli Lilly Q4 results, ADP data: What to Watch (Yahoo Finance Video)
05:55PM	2 Healthcare Dividend Stocks That are Just What the Doctor Ordered (Motley Fool)
11:18AM	Silver Economy Boom: Investing in Healthcare's Aging Tailwinds (Zacks)
08:50AM	Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle Testimonial Program (PR Newswire)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	234.39	18,668	4,375,585		Mar 02 04:05 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	172.62	22,381	3,863,458	60,518	Feb 27 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	230.00	22,381	5,147,630	38,137	Feb 27 05:00 PM
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	230.00	22,381	5,147,630		Feb 25 04:49 PM
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Option Exercise	79.02	25,700	2,030,814	112,066	Apr 02 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 31 '25	Sale	210.08	58,832	12,359,504	53,234	Apr 02 05:00 PM
Stewart Jeffrey Ryan	Officer	Mar 31 '25	Proposed Sale	210.09	58,832	12,359,897		Mar 31 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Mar 14 '25	Sale	212.34	17,644	3,746,527	11,577	Mar 18 05:00 PM
Reents Scott T	Officer	Mar 14 '25	Proposed Sale	212.35	17,644	3,746,628		Mar 14 04:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience